AP NEWS

Idiopathic Short Stature - 2018 Pipeline Insights featuring Bolder Biotech, Braasch Biotech, Dong-A Socio, LG Life Sciences, and Myungmoon Pharma - ResearchAndMarkets.com

September 7, 2018

DUBLIN--(BUSINESS WIRE)--Sep 7, 2018--The “Idiopathic Short Stature - Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Idiopathic Short Stature development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type

Pipeline Products covered across the following Developmental Stages:

Clinical Non-clinical Inactive: Discontinued and/or Dormant

Scope

The report provides a snapshot of the pipeline development for Idiopathic Short Stature The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for Idiopathic Short Stature The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Idiopathic Short Stature The report also covers the dormant and discontinued pipeline projects related to Idiopathic Short Stature Companies FeaturedBolder BiotechnologyBraasch Biotech LLCDong-A Socio GroupLG Life SciencesMyungmoon Pharmaceutical Co.

Key Topics Covered

1. Report Introduction

2. Idiopathic Short Stature Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for Idiopathic Short Stature

4. Comparative Analysis

5. Products in Clinical Stage

5.1 Drug Name: Company Name

Product DescriptionResearch and DevelopmentProduct Development Activities

6. Products in Pre-Clinical and Discovery Stage

6.1 Drug Name: Company Name

Product DescriptionResearch and DevelopmentProduct Development Activities

7. Therapeutic Assessment

Assessment by Route of AdministrationAssessment by Stage and Route of AdministrationAssessment by Molecule TypeAssessment by Stage and Molecule Type

8. Inactive Products

8.1 Drug Name: Company Name

Product DescriptionResearch and DevelopmentProduct Development Activities

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/l2fkdb/idiopathic_short?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180907005294/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/07/2018 10:42 AM/DISC: 09/07/2018 10:41 AM

http://www.businesswire.com/news/home/20180907005294/en

AP RADIO
Update hourly